Remyelination therapies are an emerging approach for treating multiple sclerosis, but development of these therapies is hampered by a lack of imaging biomarkers. Imaging with improved specificity to myelin, as compared to conventional MRI, have the potential to act as biomarkers, but current implementations can be time consuming. We examine the performance of fast version of myelin imaging from the perspective of reproducibility, a necessary prerequisite for use in proof-of-concept clinical trials of remyelinating agents.
This abstract and the presentation materials are available to members only; a login is required.